



Special Import Permit Use

PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) is under special import permit by the Instituto para a Supervisão e Administração Farmacêutica do Governo da Região Administrativa Especial de Macau for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Healthcare Professionals can refer to the “FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVID™” and “FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS” on the PAXLOVID™ product information (United States) page:

**US FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY
USE AUTHORIZATION FOR PAXLOVID™**

**US FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS”
on the PAXLOVID™**

For reference only, “PAXLOVID™ Patient Information Leaflet” in Chinese can be accessed below. Variations are presence against the US “FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS”:

PAXLOVID™ Patient Information Leaflet (Chinese)